CG Oncology’s upsized IPO will support pivotal testing of cretostimogene, an oncolytic virus for non-muscle invasive bladder cancer. The clinical program spans tests of the engineered virus as a monotherapy and as part of combination treatments.
Bladder Cancer Therapies Developer Raises $380M in the First Biotech IPO of 2024
